Effect of pamidronate infusion time on renal function in patients with multiple myeloma;Influencia del tiempo de perfusión de pamidronato en la función renal de pacientes con mieloma múltiple

Farmacia Hospitalaria

Volumn 34, Issue 1, 2010, Pages 23-26

  Sierra, F ^a   Roman E ^a   Barreda, C ^a   Moleon M ^a   Pastor, J ^a   Navarro, A ^b  

^a Servicio de Farmacia   (Spain)

^b Servicio de Hematología   (Spain)

Author keywords

Adverse effects; Biphosphonates; Bone metastasis; Multiple myeloma; Pamidronate; Renal failure; Zoledronate

Indexed keywords

PAMIDRONIC ACID;

ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL LITERATURE; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 75849131655     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2009.09.003     Document Type: Article

References (17)

1. Coleman R.E. Management of bone metastases. The Oncologist 5 (2000) 463-470
2. Kanis J.A., and McCloskey E.V. Bisphosphonates in multiple myeloma. Cancer 88 (2000) 3022-3032
3. Gridelli C. The use of bisphosphonates in elderly cancer patients. The Oncologist 12 (2007) 62-71
4. Cristofanilli M., and Hortobagyi G.N. Bisphosphonates in the management of breast cancer. Cancer control 6 (1999) 241-246
5. Hortobagyi G.N., Theriault R.L., Porter L., Blaney D., Lipton A., Sinoff C., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 (1996) 1785-1791
6. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in qreducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 (1996) 488-493
7. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
8. Zervas K., Verrou E., Teleioudis Z., Vahtsevanos K., Banti A., Mihou D., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134 (2006) 620-623
9. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
10. ® [consultado12/11/2008]. Disponible en: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=62132&formato=pdf&formulario=FICHAS
11. American Society of Clinical Oncology 2007 Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-72.
12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. Disponible en: http://ctep.cancer.gov.
13. Levey A.S., Bosch J.P., Lewis J.B., Greend T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
14. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bifosfonatos para el mieloma múltiple (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 3.. Oxford: Update Software Ltd.; 2008. Disponible en: http://www.update-software.com.
15. Fernández-Fresnedo G., De Francisco A.L., Rodrigo E., Pinera C., Herráez I., Ruíz J.C., et al. Insuficiencia renal "oculta" por valoración de la función renal mediante la creatinina sérica. Nefrología 22 (2002) 95-97
16. Strocchi E., Fiumi N., Mulé R., Malini P.L., and Ambrosioni E. Plasma creatinine greatly underestimates the degree of renal function impairment in elderly inpatients. J of Hypertens 21 (2003) S84
17. Duncan L., Heathcote J., Djurdjev O., and Levian A. Screening for renal disease using serum creatinine. What are we missing?. Nephrol Dial Transplant 16 (2001) 1042-1046